Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Cardiac Tech Start-Up Partners with Mayo Clinic

Digital pulse time-series image

(romnyyepez, Pixabay.

28 Sept. 2023. A new company developing digital cardiac diagnostics is collaborating with the Mayo Clinic on early detection of coronary artery disease, a key trigger of heart attacks. AccuLine in Petah-Tikva, Israel says the licensing agreement also calls for Mayo Clinic in Rochester, Minnesota to make an investment in the company, but further financial details are not disclosed.

AccuLine, founded in 2022, is developing a system called CORA to quickly and non-invasively collect key indicators of a person’s heart and breathing activity, such as cardiac electrical signals, blood oxygen saturation, and respiratory rhythm. The company says a single four-minute CORA test by any clinician yields data for analysis with artificial intelligence algorithms that creates a 3-D image of the heart’s electrical activity and helps calculate two key electrical signals. Those two indicators, says AccuLine, offer an assessment of an individual’s coronary arteries and likelihood of coronary artery disease.

Most current diagnostics for coronary artery disease or CAD, says the company, are either less accurate, require invasive procedures, or expensive. AccuLine says a clinical study shows the CORA system returns true-positive sensitivity of 85 percent, with comparable true-negative specificity.

One of Acculine’s founders and its chief medical officer is Aaron Frimmerman, director of the interventional cardiology unit at Hillel Yaffe Medical Center in Hadera, Israel. Frimmerman studies coronary artery disease, a condition caused by plaque accumulations in arteries, and the most common form of heart disease in the U.S. His research includes studies of imaging and other diagnostics for detecting the disorder.

“Proactively identify individuals at high risk”

“We are confident,” says Frimmerman in an AccuLine statement released through Cision, “that the advancement of the technology will pave the way for a solution to address a pressing unmet need related to the world’s leading cause of mortality.” He adds, “we are not only striving to transform CAD detection but also aiming to empower health care professionals with a tool that can proactively identify individuals at high risk for heart attacks.”

The agreement, says AccuLine, calls for the company and Mayo Clinic to collaborate on advancing CORA for the U.S. market, with the goal of making the system the preferred diagnostic tool for detecting coronary artery disease. AccuLine and Mayo Clinic will conduct a comprehensive clinical study needed for review by the Food and Drug Administration, and tailor the system’s workflow for adoption by primary care providers and cardiologists.

AccuLine says the agreement gives Mayo Clinic a know-how license, in effect rights to non-patentable elements in the technology, and Mayo Clinic is taking an equity stake in the company.  No other details of the deal are disclosed.

Moshe Barel, CEO of AccuLine notes, “Mayo Clinic’s extensive clinical experience and expertise in diagnosing and treating cardiac conditions are important assets as we refine CORA, enabling the identification of individuals at high risk for heart attacks years in advance.”

More from Science & Enterprise:

We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the entire page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.

*     *     *


Comments are closed.